Herpes Simplex Virus Esophagitis: Symptoms & Treatment
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in adults...
- The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- These findings primarily impact individuals with obesity *and* pre-existing cardiovascular disease.
Ozempic and Cardiovascular Risk: New Findings Demand Closer scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated meaningful weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. Importantly, the trial population already had pre-existing cardiovascular disease, including a history of heart attack, stroke, or peripheral artery disease. The average weight loss in the semaglutide group was substantial – approximately 15% of their initial body weight.
| Event | Semaglutide Group (%) | Placebo Group (%) |
|---|---|---|
| Cardiovascular Death | 3.7 | 2.9 |
| Non-Fatal Stroke | 2.6 | 2.2 |
| Non-Fatal Heart Attack | 2.2 | 1.8 |
| MACE (Combined) | 6.5 | 4.9 |
Who is Affected? Understanding the Patient Profile
These findings primarily impact individuals with obesity *and* pre-existing cardiovascular disease. The SELECT trial specifically enrolled participants with a body mass index (BMI) of 27 or higher, and established cardiovascular disease. It’s crucial to emphasize that this study does *not* suggest a similar risk for individuals using semaglutide for type 2 diabetes management,or for those with obesity but no prior heart conditions.However, it does raise questions about the broader use of GLP-1 receptor agonists in vulnerable populations.
the study’s inclusion criteria were very specific: participants had to have a history of established cardiovascular disease, meaning they had already experienced events like heart attack, stroke, or peripheral artery disease. This is a critical distinction,as the risk profile may differ significantly in individuals without such a history.
Why Does This Matter? The Implications for Clinical Practise
The SELECT trial results necessitate a more cautious approach to prescribing semaglutide and other GLP-1 receptor agonists. Physicians should carefully assess the cardiovascular risk profile of their patients before initiating treatment, particularly those with pre-existing heart conditions. Shared decision-making, where the potential benefits and risks are thoroughly discussed with the patient, is paramount. This also highlights the need for long-term cardiovascular outcome studies for all GLP-1 receptor agonists, not just semaglutide.